Understanding the pathogenetic mechanisms of SIRS and sepsis and development of innovative therapies of sepsis

Naoki Aikawa, Seitaro Fujishima

研究成果: Article査読

抄録

The concept of systemic inflammatory response syndrome (SIRS) was introduced in 1992 to define and objectively diagnose sepsis. Over the last decade, the definition of sepsis has been used for inclusion criteria of multicenter trials to develop innovative therapies of sepsis. With the recent understanding of the pathogenetic mechanisms of sepsis, many drugs have been tested, but only two drugs (activated protein C and neutrophil-elastase inhibitor) have been approved for clinical use in sepsis or SIRS. Further understanding of basic pathophysiology of SIRS and sepsis holds promise to develop a new therapeutic strategy to improve survival of patients with SIRS and sepsis.

本文言語English
ページ(範囲)2173-2176
ページ数4
ジャーナルNippon rinsho. Japanese journal of clinical medicine
62
12
出版ステータスPublished - 2004 12月

ASJC Scopus subject areas

  • 医学一般

フィンガープリント

「Understanding the pathogenetic mechanisms of SIRS and sepsis and development of innovative therapies of sepsis」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル